Trevi Therapeutics announced that additional analyses from its Phase 2a CANAL trial would be presented at CHEST 2024 in October. The presentation will include cough data from 38 idiopathic pulmonary fibrosis (IPF) patients who completed at least one treatment period.
Post-hoc analyses demonstrated a significant increase in relief-of-cough time, reduced cough time, and reduced cough intensity in IPF patients treated with nalbuphine ER compared to placebo. These findings provide further evidence of Haduvio's potential in addressing chronic cough in IPF.
The safety results of the trial were generally consistent with the known safety profile of nalbuphine ER from previous trials. The most frequently reported adverse events included nausea, dizziness, and anxiety.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.